LAUSR

or violaceous papules, and usually appears 1–12 months after being exposed to an offending agent.3 Typically, the eruption will resolve weeks to months after the offending agent is stopped.3 Previously, LDE has never been described in association with anastrozole. It is diagnosed based on physical examination, by establishing a temporal relationship between the start of medication and appearance of skin lesions, and skin biopsy.3 Treatment involves discontinuing the offending agent, along with topical and systemic steroids, depending on severity.4 Therefore, we stopped anastrozole and treated the rash with topical steroids and cetirizine for symptomatic relief. When symptoms improved, we started the patient on exemestane. She was seen in clinic 1 month after starting exemestane and reported further improvement of the pre-existing rash. Unfortunately, she developed painful oral lesions, and exemestane therapy was stopped. She is no longer taking an aromatase inhibitor and reported complete resolution of her symptoms.